Supplementary Online Content

Dunlop H, Fitzpatrick E, Kurti K, et al. Participation of patients from racial and ethnic minority groups in phase 1 early cancer drug development trials in the US, 2000-2018. *JAMA Netw Open.* 2022;5(11):e2239884.
doi:10.1001/jamanetworkopen.2022.39884

eTable. Demographics of Participants in All Phase I Trials, Industry Funded Trials, and Trials Conducted at Academic Centers Including Trials Targeting EGFR+ Non-Small Cell Lung Cancers
eFigure. Incidence by Race and Ethnicity in All Phase I Trials Including Trials Targeting EGFR+ Non-Small Cell Lung Cancers

This supplementary material has been provided by the authors to give readers additional information about their work.
**eTable.** Demographics of Participants in All Phase I Trials, Industry Funded Trials, and Trials Conducted at Academic Centers Including Trials Targeting EGFR+ Non-Small Cell Lung Cancers

|                         | AI/AN | API    | Black  | H/L    | White  |
|-------------------------|-------|--------|--------|--------|--------|
| **All Phase I**         | (n=9,273) |       |        |        |        |
| All Phase I             | 24    | 870    | 531    | 405    | 7,560  |
| 2001-2011               | 10    | 126    | 253    | 164    | 2,906  |
| 2012-2018               | 14    | 744    | 278    | 241    | 4,654  |
| **Industry**            | (n=8,215) |       |        |        |        |
| Industry                | 20    | 824    | 425    | 359    | 6,698  |
| 2001-2011               | 10    | 107    | 181    | 131    | 2,418  |
| 2012-2018               | 10    | 717    | 244    | 288    | 4,280  |
| **Academic**            | (n=7,724) |       |        |        |        |
| Academic                | 17    | 822    | 436    | 392    | 6,426  |
| 2001-2011               | 10    | 111    | 205    | 139    | 2,425  |
| 2012-2018               | 7     | 711    | 231    | 163    | 4,001  |

© 2022 Dunlop H et al. *JAMA Network Open.*
**eFigure.** Incidence by Race and Ethnicity in All Phase I Trials Including Trials Targeting EGFR+ Non-Small Cell Lung Cancers

Proportion by Race and Ethnicity

|                | Al/AN | API   | Black | Hispanic/Latinx | White |
|----------------|-------|-------|-------|-----------------|-------|
| CINA 2000-2011 | 0.57% | 2.68% | 11.5% | 2.68%           | 84.9% |
| Trials 2000-2011| 0.30% | 3.70% | 7.50% | 8.90%           | 85.8% |
| CINA 2012-2018 | 0.68% | 3.39% | 12.2% | 3.39%           | 82.9% |
| Trials 2012-2018| 0.24% | 12.7% | 54.70%| 7.30%           | 79.1% |

p<0.05*, p<0.01*, p<0.001***